Loading
Life sciences · Interventional Study
ClinicalTrials.gov · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05558605). This is a study registration, not published results. Lead sponsor: Baker Heart and Diabetes Institute. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 612 participants (ESTIMATED). Conditions: Heart Failure, Valve Heart Disease. Interventions: DIAGNOSTIC_TEST: AI-guided echo; DIAGNOSTIC_TEST: Standard echo. Primary outcome measures: Diagnosis of cardiac dysfunction or heart valve disease , 12 months. Brief summary: Heart Failure and valvular heart disease are disproportionate problems in rural and remote Australia (RRA). Echocardiography is the best imaging investigation, and essential for management, but access to this essential test shows huge geographic variations, primarily because of dependence on expert acquisition. This trial seeks to demonstrate the effectiveness of artificial intelligence-based echocardiography for triage and management of patients with known or suspected heart disease in RRA.